Relation between sarcopenia and dose-limiting toxicity in patients with metastatic colorectal cancer who received regorafenib.
Ali GökyerA KüçükardaO KöstekM B HacıoğluB S SunalN C DemircanS UzunoğluS SolakK İşseverI ÇiçinB ErdoğanPublished in: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico (2019)
Dose-limiting toxicity was significantly higher in basally sarcopenic patients who were started regorafenib as treatment of metastatic colorectal carcinoma. There was no significant relationship between overall survival and progression-free survival with sarcopenia.